Q4 2025 earnings call recap: revenue beat, 2026 guidance, margin expansion outlook, and product pipeline catalysts.

Strong growth and a bold new product lineup keep investors interested, but high valuation and shaky margins make this stock a high-wire act. Repligen Corporation (NASDAQ: RGEN) makes the tools that ...

Repligen’s third quarter saw revenue and non-GAAP profit exceed Wall Street expectations, yet the market responded negatively. Management attributed the quarter’s strong top-line performance to double ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Repligen’s Q3 Earnings Call: Strong ...

FOOTNOTES FOR ALL TABLES ABOVE (amounts in thousands, except share data): (1) In July 2023, we began restructuring activities to simplify and streamline our organization and strengthen the overall ...

Revenue of $189 million, year-over-year increase of 22% as reported and 18% organic with double-digit reported growth across all franchises Orders increased sequentially and greater than 20% year-over ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest announcement is out from Drone ...

Repligen Corporation reported its first-quarter 2025 earnings, showcasing a robust financial performance that exceeded analyst expectations. The company achieved an adjusted EPS of $0.39, surpassing ...

Messenger ribonucleic acid (mRNA) is a single-stranded molecule of RNA that carries the instructions from DNA to create specific proteins. The main applications for mRNA include immunotherapy, protein ...

H.C. Wainwright lowered the firm’s price target on Repligen (RGEN) to $180 from $240 and keeps a Buy rating on the shares. The firm says the company could generate solid top- and bottom-line growth in ...